Notice Number: NOT-HL-18-608
Key Dates
Release Date: March 28, 2018
PA-18-702
Issued by
National Heart, Lung, and Blood Institute (NHLBI)
Purpose
The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in PA-18-702 "Administrative Supplements for Participation in the Concept to Clinic: Commercializing Innovation (C3i) Program (Admin Supp - Clinical Trial Not Allowed)."
The following sections of PA-18-702 have been updated to reflect participation of NHLBI participation in this Funding Opportunity Announcement.
Components of Participating Organizations
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Heart, Lung, and Blood Institute (NHLBI)
Part 2. Section VII. Agency Contacts
Scientific/Research Contact(s)
Mike Pieck
National Heart Lung and Blood Institute (NHLBI)
Telephone: 301-496-2149
Email: NHLBI_SBIR@mail.nih.gov
Grants Management Contact(s)
Ann Marie Brasile Mejac
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0164
Email: brasilea@nhlbi.nih.gov
All other aspects of the FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Mike Pieck
National Heart Lung and Blood Institute (NHLBI)
Telephone: 301-496-2149
Email: NHLBI_SBIR@mail.nih.gov
and Human Services (HHS)
